
Predictive Oncology POAI
Annual report 2025
added 03-31-2026
Predictive Oncology Deferred Revenue 2011-2026 | POAI
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 K | 224 K | 302 K | 602 K | 187 K | 53 K | 40.4 K | 23.1 K | 6.66 K | 8 K | 5 K | 5 K | 69 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 602 K | 5 K | 128 K |
Quarterly Deferred Revenue Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 K | 149 K | 152 K | 224 K | 257 K | 270 K | 304 K | 302 K | 375 K | 628 K | 639 K | 602 K | 495 K | 531 K | 183 K | 187 K | 153 K | 154 K | 154 K | 53 K | 53 K | 53 K | 53 K | 40.4 K | 40.4 K | 40.4 K | 40.4 K | 23.1 K | 23.1 K | 23.1 K | 23.1 K | 6.66 K | 10.2 K | 14.2 K | 14.4 K | 8 K | 8 K | 8 K | 8 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 69 K | 69 K | 69 K | 69 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 639 K | 5 K | 133 K |
Deferred Revenue of other stocks in the Medical instruments industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Luminex Corporation
LMNX
|
21.1 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
59.8 K | - | -9.52 % | $ 20.6 M | ||
|
Repligen Corporation
RGEN
|
17.1 M | $ 117.78 | -0.46 % | $ 6.56 M | ||
|
Antares Pharma, Inc.
ATRS
|
3.94 M | - | - | $ 955 M | ||
|
Ekso Bionics Holdings
EKSO
|
1.73 M | $ 9.4 | -11.74 % | $ 22.8 M | ||
|
Cantel Medical Corp.
CMD
|
26.2 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
26.8 K | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
110 M | - | -0.05 % | $ 10.3 B | ||
|
Haemonetics Corporation
HAE
|
43.3 M | $ 56.83 | 1.05 % | $ 2.86 B | ||
|
ICU Medical
ICUI
|
33.8 M | $ 123.31 | -1.53 % | $ 3.04 B | ||
|
Varian Medical Systems, Inc.
VAR
|
782 M | - | -0.02 % | $ 16.3 B | ||
|
Intuitive Surgical
ISRG
|
507 M | $ 452.07 | -2.67 % | $ 161 B | ||
|
Harvard Bioscience
HBIO
|
3.45 M | $ 5.2 | 2.16 % | $ 231 M | ||
|
AngioDynamics
ANGO
|
200 K | $ 10.31 | -13.65 % | $ 421 M | ||
|
Repro Med Systems
KRMD
|
125 K | $ 4.32 | 1.17 % | $ 200 M | ||
|
Pulse Biosciences
PLSE
|
16 K | $ 23.0 | -0.13 % | $ 1.55 B | ||
|
Masimo Corporation
MASI
|
95.5 M | $ 178.59 | 0.33 % | $ 9.52 B | ||
|
iRhythm Technologies
IRTC
|
4.2 M | $ 116.8 | -1.2 % | $ 3.74 B | ||
|
Merit Medical Systems
MMSI
|
572 K | $ 67.7 | -0.78 % | $ 4 B | ||
|
BioLife Solutions
BLFS
|
103 K | $ 19.51 | 1.14 % | $ 899 M | ||
|
STERIS plc
STE
|
160 M | $ 218.71 | -0.56 % | $ 21.6 B | ||
|
OraSure Technologies
OSUR
|
1.52 M | $ 3.08 | 0.98 % | $ 226 M | ||
|
West Pharmaceutical Services
WST
|
51.9 M | $ 254.8 | 0.82 % | $ 18.4 B | ||
|
DENTSPLY SIRONA
XRAY
|
74 M | $ 11.63 | -0.26 % | $ 2.32 B | ||
|
ResMed
RMD
|
109 M | $ 224.09 | 0.56 % | $ 32.7 B | ||
|
Baxter International
BAX
|
141 M | $ 16.68 | -0.6 % | $ 8.56 B | ||
|
NeuroMetrix
NURO
|
1.96 M | - | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
3.75 M | $ 20.21 | 4.55 % | $ 1 B | ||
|
Stereotaxis
STXS
|
5.68 M | $ 1.87 | 1.08 % | $ 170 M | ||
|
The Cooper Companies
COO
|
128 M | $ 70.17 | -1.76 % | $ 14 B | ||
|
LeMaitre Vascular
LMAT
|
552 K | $ 108.49 | -0.24 % | $ 2.46 B | ||
|
Microbot Medical
MBOT
|
16.8 K | $ 2.4 | 1.27 % | $ 110 M | ||
|
Nephros
NEPH
|
70 K | $ 2.87 | -2.21 % | $ 29.8 M | ||
|
Envista Holdings Corporation
NVST
|
185 M | $ 25.81 | -0.35 % | $ 4.34 B | ||
|
Milestone Scientific
MLSS
|
340 K | $ 0.28 | -4.86 % | $ 23 M | ||
|
Alcon
ALC
|
581 M | $ 74.56 | -1.26 % | $ 40.4 B | ||
|
Pro-Dex
PDEX
|
202 K | $ 51.67 | 1.33 % | $ 170 M | ||
|
Retractable Technologies
RVP
|
353 K | $ 0.69 | 2.99 % | $ 20.7 M |